1. Agency EM (2017) Ibrutinib [monograph on the internet]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/human_med_001801.jsp&mid=WC0b01ac058001d124
2. AstraZeneca (2017a) Prescribing information of CALQUENCE (acalabrutinib) [monograph on the internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf
3. AstraZeneca (2017b) S FDA approves AstraZeneca’s Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma [monograph on the internet]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html
4. Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, van Hoek M, de Zwart E, Mittag D, Demont D, Verkaik S, Krantz F, Pearson PG, Ulrich R, Kaptein A (2017) Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther 363:240–252
5. Bojarczuk K, Bobrowicz M, Dwojak M, Miazek N, Zapala P, Bunes A, Siernicka M, Rozanska M, Winiarska M (2015) B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells Mol Dis 55:255–265